HRP20170081T1 - Cjepivo protiv virusa varicela zoster - Google Patents
Cjepivo protiv virusa varicela zoster Download PDFInfo
- Publication number
- HRP20170081T1 HRP20170081T1 HRP20170081TT HRP20170081T HRP20170081T1 HR P20170081 T1 HRP20170081 T1 HR P20170081T1 HR P20170081T T HRP20170081T T HR P20170081TT HR P20170081 T HRP20170081 T HR P20170081T HR P20170081 T1 HRP20170081 T1 HR P20170081T1
- Authority
- HR
- Croatia
- Prior art keywords
- vzv
- antigen
- live attenuated
- use according
- vzv antigen
- Prior art date
Links
- 229940124863 Varicella-zoster virus vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 230000002238 attenuated effect Effects 0.000 claims 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (10)
1. Upotreba VZV antigena gE u pripravi medikamenta za istodobnu ili uzastopnu primjenu uz živi oslabljeni VZV radi sprječavanja ili smanjivanja težine herpes zostera i/ili postherpetične neuralgije kod osoba koje su u opasnosti od takvih bolesti, naznačena time što je VZV antigen gE antigen gE, skraćen kako bi se uklonilo C-terminalno sidrišno područje, gdje se VZV antigen unosi uz adjuvans koji sadrži 3D-MPL, QS21 i liposome koji sadrže kolesterol.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što je živi oslabljeni VZV oslabljeni VZV soj OKA.
3. Upotreba u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se VZV antigen gE unosi u pristupu s početnim stimulansom prije živog oslabljenog VZV.
4. Upotreba u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se VZV antigen gE unosi u pristupu s početnim stimulansom nakon živog oslabljenog VZV.
5. Komplet, naznačen time što sadrži živi oslabljeni VZV i, odvojeno, VZV antigen gE, skraćen kako bi se uklonilo C-terminalno sidrišno područje, u kombinaciji s adjuvansom koji sadrži 3D-MPL, QS21 i liposomima koji sadrže kolesterol, gdje su te komponente pogodne za istodobni ili uzastopni unos, ili za miješanje u jedinstveni pripravak prije unosa.
6. VZV antigen gE, skraćen kako bi se uklonilo C-terminalno sidrišno područje, u kombinaciji s adjuvansom koji sadrži 3D-MPL, QS21 i liposomima koji sadrže kolesterol, naznačen time što je namijenjen upotrebi kao medikament za istodobnu ili uzastopnu primjenu uz živi oslabljeni VZV radi sprječavanja ili smanjivanja težine herpes zostera i/ili postherpetične neuralgije kod osoba koje su u opasnosti od takvih bolesti.
7. VZV antigen gE namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što se VZV antigen gE unosi u pristupu s početnim stimulansom prije živog oslabljenog VZV.
8. VZV antigen gE namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što se VZV antigen gE unosi u pristupu s početnim stimulansom nakon živog oslabljenog VZV.
9. VZV antigen gE namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačen time što je živi oslabljeni VZV oslabljeni VZV soj OKA.
10. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 4, komplet u skladu s patentnim zahtjevom 5 ili VZV antigen gE u skladu s bilo kojim od patentnih zahtjeva 6 do 9, naznačen time što VZV antigen gE ima slijed SEQ ID No 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0504436.7A GB0504436D0 (en) | 2005-03-03 | 2005-03-03 | Vaccine |
| EP10188214.0A EP2281830B1 (en) | 2005-03-03 | 2006-03-01 | Varicella Zoster virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170081T1 true HRP20170081T1 (hr) | 2017-03-24 |
Family
ID=34430592
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150142TT HRP20150142T1 (hr) | 2005-03-03 | 2015-02-04 | Cjepivo protiv virusa varicella zoster |
| HRP20170081TT HRP20170081T1 (hr) | 2005-03-03 | 2017-01-18 | Cjepivo protiv virusa varicela zoster |
| HRP20180989TT HRP20180989T1 (hr) | 2005-03-03 | 2018-06-26 | Cjepivo protiv virusa varicela-zoster |
| HRP20180988TT HRP20180988T1 (hr) | 2005-03-03 | 2018-06-26 | Cjepivo protiv virusa varicela-zoster |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150142TT HRP20150142T1 (hr) | 2005-03-03 | 2015-02-04 | Cjepivo protiv virusa varicella zoster |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180989TT HRP20180989T1 (hr) | 2005-03-03 | 2018-06-26 | Cjepivo protiv virusa varicela-zoster |
| HRP20180988TT HRP20180988T1 (hr) | 2005-03-03 | 2018-06-26 | Cjepivo protiv virusa varicela-zoster |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20080171079A1 (hr) |
| EP (4) | EP2281831B1 (hr) |
| JP (2) | JP5420842B2 (hr) |
| KR (2) | KR20140006115A (hr) |
| CN (2) | CN103028113B (hr) |
| AR (2) | AR052498A1 (hr) |
| AU (1) | AU2006222225B2 (hr) |
| BR (1) | BRPI0607840B1 (hr) |
| CA (2) | CA2600905C (hr) |
| CY (5) | CY1116108T1 (hr) |
| DK (4) | DK2301955T3 (hr) |
| EA (1) | EA011884B1 (hr) |
| ES (4) | ES2675055T3 (hr) |
| GB (1) | GB0504436D0 (hr) |
| HK (1) | HK1111427A1 (hr) |
| HR (4) | HRP20150142T1 (hr) |
| HU (4) | HUE038468T2 (hr) |
| IL (1) | IL185442A (hr) |
| LT (4) | LT2301955T (hr) |
| LU (1) | LUC00087I2 (hr) |
| MA (1) | MA29714B1 (hr) |
| MX (2) | MX2007010626A (hr) |
| MY (1) | MY148464A (hr) |
| NL (1) | NL300951I2 (hr) |
| NO (2) | NO341841B1 (hr) |
| NZ (1) | NZ561075A (hr) |
| PE (2) | PE20061287A1 (hr) |
| PL (4) | PL2281830T3 (hr) |
| PT (4) | PT1858917E (hr) |
| SI (4) | SI2301955T1 (hr) |
| TR (2) | TR201809397T4 (hr) |
| TW (1) | TWI403517B (hr) |
| UA (1) | UA94900C2 (hr) |
| WO (1) | WO2006094756A2 (hr) |
| ZA (1) | ZA200707144B (hr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| US20100330122A1 (en) * | 2007-07-19 | 2010-12-30 | Gale Smith | VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS |
| FR2952825B1 (fr) | 2009-11-24 | 2012-05-25 | Goaster Jacqueline Le | Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2 |
| EP2590626B1 (en) | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes with lipids having an advantageous pka-value for rna delivery |
| PT2591114T (pt) | 2010-07-06 | 2016-08-02 | Glaxosmithkline Biologicals Sa | Imunização de mamíferos de grande porte com doses baixas de arn |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| UA112970C2 (uk) * | 2010-08-05 | 2016-11-25 | Мерк Шарп Енд Доме Корп. | Інактивований вірус вітряної віспи, спосіб його одержання і застосування |
| HRP20221023T1 (hr) | 2010-08-31 | 2022-11-11 | Glaxosmithkline Biologicals S.A. | Pegilirani liposomi za isporuku rna koja kodira imunogen |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| ES2656050T3 (es) | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Composiciones de combinación inmunogénica y usos de las mismas |
| US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| EP3053591A4 (en) * | 2013-10-03 | 2017-04-19 | Nitto Denko Corporation | Injectable vaccine composition |
| JP6499420B2 (ja) * | 2014-11-13 | 2019-04-10 | 公益財団法人ヒューマンサイエンス振興財団 | ワクチン及び感染防御キット |
| CN107106675A (zh) * | 2014-12-18 | 2017-08-29 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗接种 |
| BE1022523B1 (fr) * | 2014-12-18 | 2016-05-20 | Glaxosmithkline Biologicals Sa | Vaccination |
| TW201729838A (zh) * | 2015-10-22 | 2017-09-01 | 現代公司 | 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗 |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| SG10202012205XA (en) | 2015-11-06 | 2021-01-28 | Adjuvance Technologies Inc | Triterpene saponin analogues |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| US10874734B2 (en) | 2016-11-25 | 2020-12-29 | Mogam Institute For Biomedical Research | Varicella zoster virus vaccine |
| WO2018097642A1 (ko) * | 2016-11-25 | 2018-05-31 | 재단법인 목암생명과학연구소 | 바리셀라 조스터 바이러스 백신 |
| CN107022559A (zh) * | 2016-12-08 | 2017-08-08 | 长春祈健生物制品有限公司 | 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| EP3560512A4 (en) * | 2016-12-26 | 2020-07-22 | Mogam Institute for Biomedical Research | COMPOSITION OF VACCINE AGAINST ZONA |
| CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
| IL292991A (en) * | 2017-04-25 | 2022-07-01 | Adjuvance Tech Inc | Triterpene saponin analogs |
| EP3615039A4 (en) * | 2017-04-25 | 2021-01-13 | Adjuvance Technologies, Inc. | TRITERPENIC SAPONIN ANALOGUES |
| EP3615061A1 (en) | 2017-04-28 | 2020-03-04 | GlaxoSmithKline Biologicals S.A. | Vaccination |
| GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| BR112019025193A2 (pt) | 2017-05-30 | 2020-06-23 | Glaxosmithkline Biologicals S.A. | Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução |
| KR20200098476A (ko) | 2017-10-16 | 2020-08-20 | 아쥬반스 테크놀로지스 인코포레이티드 | 트리테르펜 사포닌 유사체 |
| MX2020005481A (es) | 2017-12-01 | 2020-12-07 | Glaxosmithkline Biologicals Sa | Purificacion de saponina. |
| CN108315344A (zh) * | 2018-02-14 | 2018-07-24 | 武汉博沃生物科技有限公司 | Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用 |
| KR20190121956A (ko) | 2018-04-19 | 2019-10-29 | 가천대학교 산학협력단 | 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물 |
| KR102337922B1 (ko) | 2018-04-19 | 2021-12-09 | 가천대학교 산학협력단 | 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물 |
| JP7247226B2 (ja) * | 2018-05-23 | 2023-03-28 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | 水痘・帯状疱疹ウイルスの抗原バリアントおよびその使用 |
| JP2021533162A (ja) | 2018-08-07 | 2021-12-02 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | プロセス及びワクチン |
| CN108992667A (zh) * | 2018-08-09 | 2018-12-14 | 安徽智飞龙科马生物制药有限公司 | 一种带状疱疹疫苗及其制备方法、应用 |
| KR102270048B1 (ko) | 2020-07-10 | 2021-06-28 | 주식회사 녹십자 | 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법 |
| CN113164586B (zh) * | 2018-09-27 | 2024-04-16 | 武汉博沃生物科技有限公司 | 免疫组合物及其制备方法与应用 |
| WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| CN114080393A (zh) | 2019-06-05 | 2022-02-22 | 葛兰素史克生物有限公司 | 皂苷纯化 |
| CN112142828B (zh) * | 2019-06-28 | 2022-02-01 | 怡道生物科技(苏州)有限公司 | 一种gE基因及表达该基因的载体 |
| US20230073321A1 (en) * | 2019-12-13 | 2023-03-09 | Grand Theravac Life Science (Nanjing) Co., Ltd. | Pharmaceutical composition and use thereof |
| KR20210110242A (ko) * | 2020-02-28 | 2021-09-07 | (주)셀트리온 | 수두 대상포진 바이러스 융합 단백질 및 이를 포함하는 면역원성 조성물 |
| WO2022031359A1 (en) | 2020-08-07 | 2022-02-10 | Infectious Disease Research Institute | Purified saponins and chromatographic process for purification of same |
| KR102660479B1 (ko) * | 2020-09-11 | 2024-04-25 | 주식회사 유바이오로직스 | 수두 또는 대상포진 백신 조성물 및 이를 이용하는 방법 |
| RU2750818C1 (ru) * | 2020-11-19 | 2021-07-05 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова | Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения |
| WO2023056912A1 (en) * | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for vzv |
| EP4416274A2 (en) | 2021-10-15 | 2024-08-21 | BioNTech SE | Pharmaceutical compositions for delivery of viral antigens and related methods |
| EP4436983A1 (en) | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Varicella-zoster virus immunogen compositions and their uses |
| CN116350770B (zh) * | 2021-12-28 | 2024-07-12 | 成都迈科康生物科技有限公司 | 一种带状疱疹疫苗制剂及其制备方法 |
| WO2024017827A1 (en) | 2022-07-19 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Continuous process for vaccine production |
| CN116655748B (zh) * | 2023-02-28 | 2024-07-26 | 易慧生物技术(上海)有限公司 | 一种截短型水痘-带状疱疹病毒gE蛋白及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5341202B2 (hr) | 1974-03-12 | 1978-11-01 | ||
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4769239A (en) | 1984-08-21 | 1988-09-06 | Merck & Co., Inc. | Vaccine against varicella-zoster virus |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE119939T1 (de) | 1989-06-27 | 1995-04-15 | Smithkline Beecham Biolog | Verbindungen. |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
| ES2143716T3 (es) * | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
| DK0651789T4 (da) * | 1992-07-17 | 2009-07-27 | Merck & Co Inc | Fremgangsmåde til at forebygge zoster eller lindre varicella-forbundet post-herpetisk neuralgia |
| DE69405551T3 (de) | 1993-03-23 | 2005-10-20 | Smithkline Beecham Biologicals S.A. | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| US5976552A (en) * | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| DK0817847T4 (da) * | 1995-03-23 | 2009-10-05 | Immunex Corp | IL-17-receptor |
| US6846489B1 (en) | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| KR0177323B1 (ko) * | 1996-02-16 | 1999-04-01 | 성재갑 | 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법 |
| CN1259052A (zh) | 1997-04-01 | 2000-07-05 | 科里克萨有限公司 | 单磷酰基脂质a的水性免疫佐剂组合物 |
| CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| GB9901254D0 (en) * | 1999-01-20 | 1999-03-10 | Smithkline Beecham Biolog | Vaccines |
| PL208755B1 (pl) * | 2000-10-18 | 2011-06-30 | Glaxosmithkline Biolog Sa | Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu |
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
-
2005
- 2005-03-03 GB GBGB0504436.7A patent/GB0504436D0/en not_active Ceased
-
2006
- 2006-03-01 TR TR2018/09397T patent/TR201809397T4/tr unknown
- 2006-03-01 PL PL10188214T patent/PL2281830T3/pl unknown
- 2006-03-01 CA CA2600905A patent/CA2600905C/en active Active
- 2006-03-01 SI SI200632264T patent/SI2301955T1/en unknown
- 2006-03-01 LT LTEP10188215.7T patent/LT2301955T/lt unknown
- 2006-03-01 HU HUE10188215A patent/HUE038468T2/hu unknown
- 2006-03-01 HU HUE10188214A patent/HUE032544T2/en unknown
- 2006-03-01 ES ES10188256.1T patent/ES2675055T3/es active Active
- 2006-03-01 EA EA200701632A patent/EA011884B1/ru not_active IP Right Cessation
- 2006-03-01 SI SI200632138A patent/SI2281830T1/sl unknown
- 2006-03-01 JP JP2007557447A patent/JP5420842B2/ja active Active
- 2006-03-01 MY MYPI20060879A patent/MY148464A/en unknown
- 2006-03-01 MX MX2007010626A patent/MX2007010626A/es active IP Right Grant
- 2006-03-01 PT PT67074468T patent/PT1858917E/pt unknown
- 2006-03-01 PT PT101882140T patent/PT2281830T/pt unknown
- 2006-03-01 DK DK10188215.7T patent/DK2301955T3/en active
- 2006-03-01 CN CN201210552767.6A patent/CN103028113B/zh active Active
- 2006-03-01 SI SI200632265T patent/SI2281831T1/en unknown
- 2006-03-01 DK DK10188256.1T patent/DK2281831T3/en active
- 2006-03-01 NZ NZ561075A patent/NZ561075A/en not_active IP Right Cessation
- 2006-03-01 HU HUE10188256A patent/HUE038467T2/hu unknown
- 2006-03-01 EP EP10188256.1A patent/EP2281831B1/en active Active
- 2006-03-01 BR BRPI0607840-0A patent/BRPI0607840B1/pt active IP Right Grant
- 2006-03-01 DK DK10188214.0T patent/DK2281830T3/en active
- 2006-03-01 US US11/817,175 patent/US20080171079A1/en not_active Abandoned
- 2006-03-01 DK DK06707446.8T patent/DK1858917T3/da active
- 2006-03-01 CN CN2006800152455A patent/CN101189254B/zh active Active
- 2006-03-01 AU AU2006222225A patent/AU2006222225B2/en active Active
- 2006-03-01 TR TR2018/09393T patent/TR201809393T4/tr unknown
- 2006-03-01 LT LTEP10188214.0T patent/LT2281830T/lt unknown
- 2006-03-01 KR KR1020137034242A patent/KR20140006115A/ko not_active Application Discontinuation
- 2006-03-01 AR ARP060100773A patent/AR052498A1/es not_active Application Discontinuation
- 2006-03-01 PE PE2006000237A patent/PE20061287A1/es not_active Application Discontinuation
- 2006-03-01 EP EP20060707446 patent/EP1858917B8/en active Active
- 2006-03-01 PT PT101882561T patent/PT2281831T/pt unknown
- 2006-03-01 ES ES10188214.0T patent/ES2618037T3/es active Active
- 2006-03-01 CA CA2882255A patent/CA2882255C/en active Active
- 2006-03-01 PL PL10188256T patent/PL2281831T3/pl unknown
- 2006-03-01 UA UAA200709537A patent/UA94900C2/uk unknown
- 2006-03-01 PE PE2010000522A patent/PE20100658A1/es not_active Application Discontinuation
- 2006-03-01 EP EP10188215.7A patent/EP2301955B1/en active Active
- 2006-03-01 LT LTEP10188256.1T patent/LT2281831T/lt unknown
- 2006-03-01 WO PCT/EP2006/002070 patent/WO2006094756A2/en active Application Filing
- 2006-03-01 PT PT101882157T patent/PT2301955T/pt unknown
- 2006-03-01 ES ES10188215.7T patent/ES2675054T3/es active Active
- 2006-03-01 PL PL06707446T patent/PL1858917T3/pl unknown
- 2006-03-01 PL PL10188215T patent/PL2301955T3/pl unknown
- 2006-03-01 KR KR1020077022672A patent/KR101357204B1/ko active Protection Beyond IP Right Term
- 2006-03-01 SI SI200631890T patent/SI1858917T1/sl unknown
- 2006-03-01 MX MX2012004471A patent/MX346865B/es unknown
- 2006-03-01 ES ES06707446.8T patent/ES2532803T3/es active Active
- 2006-03-01 TW TW095106863A patent/TWI403517B/zh not_active IP Right Cessation
- 2006-03-01 EP EP10188214.0A patent/EP2281830B1/en active Active
-
2007
- 2007-08-22 IL IL185442A patent/IL185442A/en active IP Right Grant
- 2007-08-23 ZA ZA200707144A patent/ZA200707144B/xx unknown
- 2007-08-29 NO NO20074392A patent/NO341841B1/no active Protection Beyond IP Right Term
- 2007-09-24 MA MA30239A patent/MA29714B1/fr unknown
-
2008
- 2008-02-25 HK HK08102085.4A patent/HK1111427A1/xx not_active IP Right Cessation
-
2010
- 2010-05-20 US US12/784,296 patent/US20110045059A1/en not_active Abandoned
-
2011
- 2011-01-07 US US12/986,928 patent/US7939084B1/en active Active
-
2013
- 2013-04-08 JP JP2013080447A patent/JP5840167B2/ja active Active
-
2015
- 2015-02-04 HR HRP20150142TT patent/HRP20150142T1/hr unknown
- 2015-02-20 CY CY20151100179T patent/CY1116108T1/el unknown
-
2017
- 2017-01-03 AR ARP170100008A patent/AR107285A2/es not_active Application Discontinuation
- 2017-01-18 HR HRP20170081TT patent/HRP20170081T1/hr unknown
- 2017-02-10 CY CY20171100188T patent/CY1118629T1/el unknown
-
2018
- 2018-06-19 CY CY20181100637T patent/CY1120347T1/el unknown
- 2018-06-19 CY CY20181100636T patent/CY1121211T1/el unknown
- 2018-06-26 HR HRP20180989TT patent/HRP20180989T1/hr unknown
- 2018-06-26 HR HRP20180988TT patent/HRP20180988T1/hr unknown
- 2018-09-17 CY CY2018025C patent/CY2018025I2/el unknown
- 2018-09-20 LT LTPA2018012C patent/LTC2281831I2/lt unknown
- 2018-09-20 LU LU00087C patent/LUC00087I2/fr unknown
- 2018-09-20 NO NO2018033C patent/NO2018033I1/no unknown
- 2018-09-20 HU HUS1800038C patent/HUS1800038I1/hu unknown
- 2018-09-20 NL NL300951C patent/NL300951I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170081T1 (hr) | Cjepivo protiv virusa varicela zoster | |
| JP2008531637A5 (hr) | ||
| Reguera et al. | Current status on prevention and treatment of canine leishmaniasis | |
| Chang et al. | Effects of pimozide and des Gly10,[D-Ala6] luteinizing hormone-releasing hormone ethylamide on serum gonadotropin concentrations, germinal vesicle migration, and ovulation in female goldfish, Carassius auratus | |
| DE69901284T2 (de) | Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern | |
| AR053680A1 (es) | Composicion | |
| HRP20170433T1 (hr) | Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci | |
| KR20120009421A (ko) | 항체 제제 | |
| Bailey et al. | Self-encapsulating poly (lactic-co-glycolic acid)(PLGA) microspheres for intranasal vaccine delivery | |
| TR201807756T4 (tr) | Sentetik adjuvan içeren aşı bileşimi. | |
| ES2558515T3 (es) | Sistema de liberación de acaro predador fitoseído y método para su producción | |
| JP2015513527A5 (hr) | ||
| JP2006506441A5 (hr) | ||
| JP2009541373A5 (hr) | ||
| Thomas et al. | Application of nitric oxide synthase inhibitor, Nω-nitro-l-arginine methyl ester, on injured nerve attenuates neuropathy-induced thermal hyperalgesia in rats | |
| HRP20150120T1 (hr) | Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam | |
| Dong et al. | Ethyl pyruvate protects against Salmonella intestinal infection in mice through down-regulation of pro-inflammatory factors and inhibition of TLR4/MAPK pathway | |
| Tian et al. | Intradermal administration of influenza vaccine with trehalose and pullulan-based dissolving microneedle arrays | |
| CN106511323B (zh) | 广藿香醇在制备防治溃疡性结肠炎的药物中的应用 | |
| Hamackova et al. | The efficacy of various anaesthetics in tench (Tinca tinca L.) related to water temperature | |
| EA200701166A1 (ru) | Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин | |
| Qu et al. | Effects of gentiana scabra bage on expression of hepatic type I, III collagen proteins in Paragonimus skrjabini rats with liver fibrosis | |
| ES2645339T3 (es) | Usos de n-butilidenftalida en el tratamiento de una lesión hepática y en la mejora de la función hepática | |
| MARWA et al. | Effects of Echinacea Purpurea on cryptosporidiosis in immunosuppressed experimentally infected mice | |
| JP2010510218A5 (hr) |